Phenotypes associated with this allele

• Allele Symbol: Tg(KRT5-rtTA)T2D6Sgkd
• Allele Name: transgene insertion T2D6, Silvio Gutkind
• Allele ID: MGI:5292234
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cx1	Col1a1^tm1(tetO-Fos)Wag/Col1a1^+ Rag1^tm1Mom/Rag1^tm1Mom Tg(KRT5-rtTA)T2D6Sgkd/0	involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * FVB/N	MGI:5555860
cx2	Col1a1^tm1(tetO-Fos)Wag/Col1a1^+ Tg(KRT5-rtTA)T2D6Sgkd/0	involves: 129S4/SvJae * C57BL/6 * FVB/N	MGI:5555858

Genotype
MGI:5555860

cx1

• Allelic Composition: Col1a1^{tm1(tetO-Fos)Wag}/Col1a1⁺; Rag1^tm1Mom/Rag1^tm1Mom; Tg(KRT5-rtTA)T2D6Sgkd/0
• Genetic Background: involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

integument

integument phenotype ( J:201145 )

N • doxycycline-treated mice exhibit normal keratinocyte proliferation and activation

skin lesions ( J:201145 )

• in doxycycline-treated mice but smaller than in mice with wild-type Rag1

skin hyperplasia ( J:201145 )

• in doxycycline-treated mice but less so than in mice with wild-type Rag1

Genotype
MGI:5555858

cx2

• Allelic Composition: Col1a1^{tm1(tetO-Fos)Wag}/Col1a1⁺; Tg(KRT5-rtTA)T2D6Sgkd/0
• Genetic Background: involves: 129S4/SvJae * C57BL/6 * FVB/N

mortality/aging

premature death ( J:201145 )

• after doxycycline treatment

integument

increased keratinocyte proliferation ( J:201145 )

• with increased survival in doxycycline-treated mice

skin inflammation ( J:201145 )

• in doxycycline-treated mice

alopecia ( J:201145 )

• after doxycycline treatment

absent hair follicles ( J:201145 )

• in doxycycline-treated mice

hyperkeratosis ( J:201145 )

• cornified epidermis in affected skin of doxycycline-treated mice

parakeratosis ( J:201145 )

• in doxycycline-treated mice

epidermal hyperplasia ( J:201145 )

• in doxycycline-treated mice

• however, MMP inhibitor impairs hyperplasia

skin lesions ( J:201145 )

• dry and scaly lesions on the affected skin of doxycycline-treated mice

skin hyperplasia ( J:201145 )

• in doxycycline-treated mice

thick skin ( J:201145 )

• affected skin of doxycycline-treated mice

immune system

immune system phenotype ( J:201145 )

N • doxycycline-treated mice exhibit normal spleen weight

increased granulocyte number ( J:201145 )

• in the skin of doxycycline-treated mice

increased CD4-positive, alpha-beta T cell number ( J:201145 )

• in the skin of doxycycline-treated mice

• however, doxycycline withdrawal restores CD4+ T cell numbers

skin inflammation ( J:201145 )

• in doxycycline-treated mice

neoplasm

increased incidence of tumors by chemical induction ( J:201145 )

• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks

• however, sulindac treatment reduces the number and size of tumors

increased papilloma incidence ( J:201145 )

• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks

growth/size/body

decreased body size ( J:201145 )

• after doxycycline treatment

digestive/alimentary system

abnormal forestomach morphology ( J:201145 )

• mild phenotype in doxycycline-treated mice

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:201145 )

• doxycycline-treated mice exposed to DMBA/TPA develop papillomas at 8 weeks that become ulcerative at 11 weeks

• however, sulindac treatment reduces the number and size of tumors

cellular

increased keratinocyte proliferation ( J:201145 )

• with increased survival in doxycycline-treated mice

hematopoietic system

increased granulocyte number ( J:201145 )

• in the skin of doxycycline-treated mice

increased CD4-positive, alpha-beta T cell number ( J:201145 )

• in the skin of doxycycline-treated mice

• however, doxycycline withdrawal restores CD4+ T cell numbers